What side effects of Ozempic are the lawsuits about?

The primary injuries are: gastroparesis (stomach paralysis), intestinal obstruction/ileus, acute pancreatitis, gallbladder disease (cholecystitis/cholelithiasis), and NAION (non-arteritic anterior ischemic optic neuropathy — sudden vision loss). Gastroparesis claims make up the majority of the MDL.

Will my gastroparesis go away if I stop taking Ozempic?

It depends. Some patients improve after discontinuing the drug, though recovery may take weeks to months. However, a significant subset of patients develop persistent gastroparesis that does not resolve — requiring ongoing medical management, dietary modifications, or surgical intervention. The persistence of symptoms after drug discontinuation strengthens the legal claim.

Can I sue if I used Ozempic for weight loss, not diabetes?

Yes. In fact, weight-loss patients represent the majority of plaintiffs in the MDL. The landmark JAMA 2023 study specifically examined GLP-1 use in non-diabetic weight-loss patients and found dramatically elevated GI risks. Whether you used Ozempic, Wegovy, or Mounjaro — and whether for diabetes or weight loss — you may have a claim if you suffered a qualifying injury.

Can the defense argue my diabetes caused my gastroparesis?

This is a common defense argument, but it can be overcome. Key factors: if your gastric function was normal before starting the GLP-1 drug (documented by prior testing or absence of GI complaints), if gastroparesis developed rapidly after drug initiation, and if you were using the drug for weight loss rather than diabetes. Pre-drug documentation of normal GI function is the strongest rebuttal.

Is Mounjaro included in the lawsuit?

Yes. Eli Lilly's Mounjaro (tirzepatide) and Zepbound are included in the MDL alongside Novo Nordisk's semaglutide products. The legal theories are the same: failure to warn about severe GI complications. Claims against both manufacturers are consolidated in the same MDL.

I had my gallbladder removed after starting Ozempic. Can I sue?

Yes. Cholecystectomy (gallbladder removal) is a direct compensable injury. Your claim would allege that the GLP-1 drug caused gallstone formation or cholecystitis that necessitated surgery. Evidence includes: surgical records, pathology reports confirming gallstones, timeline showing gallbladder disease developed after starting the drug, and no prior gallbladder problems.

What is gastroparesis and is it permanent?

Gastroparesis is a condition where the stomach cannot empty food normally. Symptoms include severe nausea, vomiting, abdominal pain, and malnutrition. When caused by GLP-1 drugs, gastroparesis may improve after stopping the medication, but in many cases it persists for months or years — and some patients develop permanent gastroparesis requiring ongoing medical management or surgery.

I lost weight rapidly on Ozempic and then got gallstones. Is that related?

Very likely. Rapid weight loss is a well-established risk factor for gallstone formation. GLP-1 drugs produce rapid weight loss AND directly affect gallbladder motility — a double risk. A systematic review of 76 RCTs found 37% higher gallbladder disease risk with GLP-1 drugs. The combination of rapid weight loss and direct pharmacological effects strengthens the causation argument.

How much are Ozempic lawsuits worth?

No trials have concluded yet — bellwether trials are expected in mid-to-late 2026. Projected settlement ranges based on comparable mass tort outcomes are: $100,000-$250,000 for mild gastroparesis, $250,000-$700,000 for severe GI injuries, and $700,000-$1,500,000+ for NAION or fatal complications. Actual values will be established by trial outcomes.

Does the gallbladder warning on the label protect the manufacturer?

Not necessarily. Even when a label includes a general warning, the manufacturer can be liable if the warning understates the magnitude of risk, fails to communicate urgency, or is not prominently positioned. Plaintiffs argue the gallbladder warnings were buried in fine print and did not convey the true frequency and severity of gallbladder complications.

How is pancreatitis diagnosed?

Acute pancreatitis is typically diagnosed through: elevated serum lipase and/or amylase levels (3x above normal), characteristic abdominal pain, and imaging (CT scan or MRI) showing pancreatic inflammation. Hospital records documenting these findings during GLP-1 use provide strong evidence for your claim.

Can I still file an Ozempic lawsuit in 2026?

Yes. New cases continue to be filed and added to the MDL. The statute of limitations typically starts at diagnosis, so recently diagnosed patients should file promptly. If you were diagnosed more than 2 years ago, the discovery rule may still protect your claim — consult an attorney immediately to evaluate your deadline.

I had pancreatitis while on Mounjaro. Is my case the same as Ozempic?

Yes. Both semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) carry pancreatitis risk through similar GLP-1 receptor mechanisms. Claims against Eli Lilly for Mounjaro-related pancreatitis follow the same legal theories as claims against Novo Nordisk for Ozempic. Both are consolidated in MDL 3094.

What is NAION and how does it relate to Ozempic?

NAION (non-arteritic anterior ischemic optic neuropathy) is a form of sudden, painless vision loss caused by inadequate blood flow to the optic nerve. Studies show semaglutide users face 4-8x higher NAION risk. The EMA required European warnings in August 2024, but Novo Nordisk has not updated U.S. labels. A separate NAION MDL (3163) was established in December 2025.

Can pancreatitis from Ozempic lead to long-term problems?

Yes. Recurrent or severe pancreatitis can lead to chronic pancreatitis — a permanent condition causing ongoing pain, malabsorption, and diabetes. Severe pancreatitis can also cause pancreatic necrosis, pseudocysts, or organ failure. Long-term complications increase the value of your claim.

Do I have to stop taking Ozempic to file a lawsuit?

No. You do not need to stop taking your medication to file a lawsuit. The decision to continue or discontinue a GLP-1 drug should be made with your doctor based on your medical needs. Your lawsuit is about the manufacturer's failure to warn, not about your decision to use the drug.

I needed emergency surgery for bowel obstruction while on Wegovy. What are my options?

Emergency bowel obstruction surgery is among the most serious GLP-1 injuries and produces the highest-value claims. Document: emergency room records, surgical records, length of hospitalization, any complications (ostomy, bowel resection), and recovery timeline. Contact an attorney immediately — your case is strong.

What is an MDL and how does it affect my case?

An MDL (multidistrict litigation) consolidates similar federal cases before a single judge for efficiency during pre-trial proceedings. Your case remains individual — your specific injuries and damages are unique. The MDL structure means shared discovery, coordinated expert testimony, and bellwether trials that inform settlement negotiations for all cases.

Is ileus the same as bowel obstruction?

Not exactly. Ileus is a functional shutdown of intestinal motility — the intestine stops moving even without a physical blockage. Bowel obstruction involves a physical blockage of the intestinal passage. Both are serious and both are listed as adverse reactions on GLP-1 labels (ileus added September 2023; intestinal obstruction added January 2025). Both support legal claims.

Will there be a class action settlement for Ozempic?

The Ozempic litigation is an MDL, not a class action. Each plaintiff has an individual case with individual damages. There is no single class action settlement. However, after bellwether trials establish value ranges, Novo Nordisk and Eli Lilly may negotiate a global settlement program similar to the Roundup or opioid settlements.

Did anyone die from Ozempic-related bowel obstruction?

Post-market reports to the FDA's FAERS system include fatalities associated with ileus and intestinal obstruction in GLP-1 users, though establishing direct causation in individual cases requires medical expert review. Wrongful death claims are among the highest-value claims in the MDL.

Is NAION vision loss permanent?

In most cases, yes. NAION causes permanent damage to the optic nerve from loss of blood flow. Some patients retain partial vision, while others experience near-total blindness in the affected eye. There is also risk of NAION developing in the second eye. There is no proven treatment to reverse NAION damage once it occurs.

How do I know if my vision loss is NAION?

NAION is diagnosed by an ophthalmologist or neuro-ophthalmologist through: examination of the optic disc (showing swelling), visual field testing (showing characteristic deficits), and ruling out other causes of optic nerve damage. If you experienced sudden, painless vision loss while taking semaglutide, seek an ophthalmology evaluation immediately and preserve all medical records.

Should I wait for bellwether trial results before filing?

No. File as soon as possible. The statute of limitations is running regardless of the MDL schedule. Filing now ensures your case is in the pipeline when settlement programs are established. There is no advantage to waiting — and significant risk if you miss your filing deadline.

How are individual settlements calculated in a pharmaceutical MDL?

If a global settlement is reached, a settlement administrator typically creates a point system based on: injury type and severity, duration of drug use, strength of causation evidence, medical expenses, lost income, and other damages. Each plaintiff receives an individual value based on their points. Higher-severity injuries receive substantially higher payments.

What percentage does the lawyer take from an Ozempic settlement?

Most Ozempic attorneys work on contingency — typically 33-40% of the recovery. You owe no fee upfront and the attorney only gets paid if you receive compensation. In MDL cases, there may also be a common benefit fund (typically 4-8%) that compensates attorneys who performed work benefiting all plaintiffs.

How big is Novo Nordisk?

Novo Nordisk is a Danish pharmaceutical giant with a market capitalization that has exceeded $500 billion. Semaglutide products generated $29.3 billion in 2024 revenue — 70% of the company's total sales. Novo Nordisk briefly became the most valuable company in Europe on the strength of its GLP-1 franchise.

Has Novo Nordisk faced lawsuits before?

Yes. Novo Nordisk has faced litigation over other products, though the GLP-1 MDL is by far the largest legal challenge in the company's history. The combination of billions in revenue, millions of patients, and serious undisclosed side effects creates unprecedented litigation exposure for the company.

Can I sue Novo Nordisk if I used generic semaglutide or a compounded version?

Claims against compounding pharmacies are separate from the MDL against Novo Nordisk. If you used FDA-approved Ozempic, Wegovy, or Rybelsus, your claim is against Novo Nordisk. If you used a compounded version, your claim may be against the compounding pharmacy. Consult an attorney to determine the right defendant for your situation.

Can I file a claim if I used Trulicity instead of Ozempic?

Yes. Trulicity (dulaglutide, made by Eli Lilly) is a GLP-1 receptor agonist included in the MDL. The same failure-to-warn theories apply to all GLP-1 drugs. The key question is whether you suffered a qualifying injury (gastroparesis, bowel obstruction, pancreatitis, etc.) during or after Trulicity use.

What is the difference between Ozempic and Wegovy?

Both contain semaglutide (made by Novo Nordisk). Ozempic is approved for type 2 diabetes at doses up to 2mg per week. Wegovy is approved for weight loss at 2.4mg per week — a higher dose. Many patients used Ozempic off-label for weight loss before Wegovy became available. Both are included in the litigation.

Is Zepbound safer than Ozempic?

There is no evidence that Zepbound (tirzepatide) is safer than Ozempic (semaglutide) regarding GI complications. Both drug classes slow gastric emptying through GLP-1 receptor activation. Mounjaro/Zepbound are included as defendants in the same MDL. Do not switch drugs without consulting your doctor, and do not assume one GLP-1 drug is safer than another.

Ozempic Vision Loss (NAION) Lawsuit - Ozempic / GLP-1 Lawsuits

People's Justice Research TeamUpdated February 24, 2026Fact-checked

Verified against court and regulatory records · No upfront fees · Your information is never sold

Free Case Review

Check your eligibility — free

Answer 2-3 quick questions to review your potential case.

Free · Confidential · About 2 minutes · A case specialist responds within 1 business day

Your answers are never sold or shared without your consent.

What Is NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy)?

NAION is a sudden loss of blood flow to the optic nerve — the nerve that transmits visual information from the eye to the brain. It typically presents as painless, sudden vision loss in one eye, often noticed upon waking. The affected eye may experience a loss of the upper or lower visual field, reduced visual acuity, and a relative afferent pupillary defect. NAION is sometimes called a 'stroke of the eye' because the mechanism is similar to a stroke — inadequate blood supply causing tissue damage. Unlike some eye conditions, NAION damage is largely irreversible. There is no proven treatment to restore vision once the optic nerve has been damaged.

The GLP-1 and NAION Connection

In July 2024, researchers at Harvard Medical School and Massachusetts Eye and Ear published a study in JAMA Ophthalmology that found patients prescribed semaglutide (Ozempic/Wegovy) had a significantly higher risk of developing NAION compared to non-users. The study analyzed medical records from over 16,000 patients and found the association held across both diabetic and non-diabetic populations. Proposed biological mechanisms include: rapid weight loss causing changes in blood viscosity, semaglutide's effects on vascular endothelial function, alterations in blood pressure regulation, and changes in the microvascular environment of the optic nerve head — an area already vulnerable due to its watershed blood supply.

The risk appears to be dose-dependent, with higher doses correlating to greater risk. Patients using GLP-1 drugs for weight loss (higher doses than diabetes management) may face elevated risk. Additional studies from multiple research institutions have corroborated the association, strengthening the scientific basis for litigation.

Ozempic Vision Loss Lawsuit Status

In December 2025, the Judicial Panel on Multidistrict Litigation (JPML) established a second federal MDL specifically for NAION and vision loss claims related to GLP-1 medications. This is separate from the existing Ozempic gastroparesis MDL. As of late 2025, approximately 2,947 lawsuits have been filed alleging NAION or other vision damage from semaglutide and tirzepatide products. Three bellwether trials have been scheduled for early 2026, with the first set for January, followed by trials in March and May. Defendants include Novo Nordisk (Ozempic, Wegovy) and Eli Lilly (Mounjaro, Zepbound).

Who Qualifies for an Ozempic NAION Lawsuit

You may qualify if you used Ozempic, Wegovy, Rybelsus (semaglutide), Mounjaro, or Zepbound (tirzepatide) and were subsequently diagnosed with NAION, experienced sudden painless vision loss in one or both eyes, or were diagnosed with optic neuropathy during or after treatment. Key documentation includes: prescription records, ophthalmology records confirming NAION diagnosis (including OCT imaging and visual field testing), and a timeline showing the temporal relationship between GLP-1 use and vision loss onset.

Symptoms of GLP-1-Related Vision Loss

NAION symptoms typically appear suddenly and may include: painless loss of vision in one eye (often noticed upon waking), blurred or dimmed vision, loss of the upper or lower half of the visual field, difficulty with contrast sensitivity, and a sensation that vision is 'washed out.' Some patients experience sequential involvement of both eyes over weeks to months. If you experience any sudden vision changes while taking a GLP-1 medication, seek immediate ophthalmologic evaluation and inform your doctor about your medication use.

How This Differs From Ozempic Gastroparesis Claims

The Ozempic litigation now involves two separate MDLs with different injuries, evidence, and timelines. The gastroparesis MDL addresses gastrointestinal injuries — severe stomach paralysis, bowel obstruction, and related digestive damage. The NAION MDL addresses vision loss and optic nerve damage. Patients may have claims in one or both MDLs depending on their injuries. The two MDLs share the same defendants (Novo Nordisk, Eli Lilly) but involve different scientific evidence and expert witnesses.

Frequently Asked Questions

Can NAION vision loss be reversed?

Unfortunately, NAION-related vision loss is generally permanent. There is currently no proven treatment to restore vision once the optic nerve has been damaged. Some patients may experience partial improvement in the weeks following the event, but most retain some degree of permanent visual deficit.

Should I stop taking Ozempic if I'm worried about NAION?

Do not stop or change any medication without consulting your prescribing physician. Your doctor can evaluate your individual risk factors and discuss the benefits and risks of continuing treatment. If you experience any sudden vision changes, seek immediate medical attention.

What is the difference between the gastroparesis and NAION lawsuits?

They are separate MDLs with different injuries. The gastroparesis MDL covers digestive injuries like stomach paralysis and bowel obstruction. The NAION MDL covers vision loss from optic nerve damage. You may qualify for one or both depending on your injuries.

Does this affect Mounjaro and Wegovy users too?

Yes. The NAION MDL covers all GLP-1 receptor agonist medications, including Ozempic, Wegovy, and Rybelsus (all semaglutide by Novo Nordisk), as well as Mounjaro and Zepbound (tirzepatide by Eli Lilly). The mechanism of injury is believed to be related to the GLP-1 drug class, not a specific brand.

Research & evidence

Scientific Evidence

cohort

Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide

Hathaway JT, Shah MP, Hathaway DB, et al. (2024). JAMA Ophthalmology

Key findings

Type 2 diabetes patients: 8.9% NAION risk on semaglutide vs 1.8% on non-semaglutide medications
Weight-loss patients: 6.7% NAION risk vs 0.8% on alternatives
Risk was highest in first year of use
Findings confirmed by Danish/Norwegian cohort study of 424,000+ patients
EMA required European label update; Novo Nordisk has not updated U.S. labels

cohort

Risk of Gastrointestinal Adverse Events Associated With GLP-1 Receptor Agonists for Weight Loss

Sodhi M, Rezaeianzadeh R, Kezouh A, Bhatt M (2023). JAMA

Key findings

Gastroparesis hazard ratio: 3.67 (95% CI 1.15-11.90)
Bowel obstruction hazard ratio: 4.22 (95% CI 1.02-17.40)
Pancreatitis hazard ratio: 9.09 (95% CI 1.25-66.00)
Study population was non-diabetic weight-loss patients — directly relevant to majority of MDL plaintiffs
Findings were robust across sensitivity analyses

meta-analysis

GLP-1 Receptor Agonists and Gallbladder Disease: A Systematic Review of Randomized Controlled Trials

Multiple authors (systematic review) (2024). Clinical Gastroenterology and Hepatology

Key findings

37% increased relative risk of gallbladder disease across 76 RCTs
Risk was more pronounced with higher doses and greater weight loss
Rapid weight loss mechanism contributes to gallstone formation
Risk increased with duration of GLP-1 agonist use
Findings support inclusion of gallbladder disease in GLP-1 litigation claims

FAQ

Frequently Asked Questions

36 QUESTIONS

Over 3,100 lawsuits allege that Novo Nordisk (maker of Ozempic, Wegovy, Rybelsus) and Eli Lilly (maker of Mounjaro, Zepbound) failed to adequately warn patients and doctors about severe side effects including gastroparesis (stomach paralysis), bowel obstruction, pancreatitis, and vision loss (NAION). The cases are consolidated in MDL 3094 in the Eastern District of Pennsylvania.

A gastric emptying scintigraphy (GES) is a 4-hour nuclear medicine test that measures how quickly food leaves your stomach. You eat a small meal containing a radioactive tracer, and a camera tracks its movement. An August 2025 MDL ruling requires gastroparesis plaintiffs to have a confirmed GES showing delayed emptying. If you are experiencing gastroparesis symptoms, getting this test is critical for both diagnosis and any legal claim.

Key evidence includes: prescription records showing which GLP-1 drug you used, dosage, and duration; medical records documenting your diagnosis (gastroparesis, bowel obstruction, pancreatitis, NAION, etc.); a gastric emptying study if gastroparesis is claimed; and records showing the condition developed after starting the drug. An August 2025 MDL ruling requires gastroparesis plaintiffs to have a confirmed gastric emptying study.

The EMA (European Medicines Agency) has a different regulatory process than the FDA. The EMA reviewed the JAMA Ophthalmology data and required label updates in August 2024. The FDA has acknowledged the studies but has not yet required a U.S. label update. This regulatory gap is central to the NAION failure-to-warn litigation — Novo Nordisk knew of the risk but chose not to voluntarily update U.S. labels.

Dive deeper

Related Guides

7 GUIDES

The full investigation

Part of the Ozempic / GLP-1 Investigation

Ozempic / GLP-1 LawsuitsGLP-1 receptor agonist drugs — including Novo Nordisk's Ozempic, Wegovy, and Rybelsus, and Eli Lilly's Mounjaro and Zepbound — have generated over $40 billion in annual sales while allegedly causing severe gastrointestinal injuries that manufacturers failed to adequately disclose. Over 3,100 lawsuits are consolidated in MDL 3094 in the Eastern District of Pennsylvania, with a separate NAION vision-loss MDL (3163) established in December 2025.CASE OVERVIEW

Ozempic Vision Loss (NAION) Lawsuit

Quick Eligibility Review

Check your eligibility — free

What Is NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy)?

The GLP-1 and NAION Connection

Ozempic Vision Loss Lawsuit Status

Who Qualifies for an Ozempic NAION Lawsuit

Symptoms of GLP-1-Related Vision Loss

How This Differs From Ozempic Gastroparesis Claims

Frequently Asked Questions

Can NAION vision loss be reversed?

Should I stop taking Ozempic if I'm worried about NAION?

What is the difference between the gastroparesis and NAION lawsuits?

Does this affect Mounjaro and Wegovy users too?

Scientific Evidence

Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide

Risk of Gastrointestinal Adverse Events Associated With GLP-1 Receptor Agonists for Weight Loss

GLP-1 Receptor Agonists and Gallbladder Disease: A Systematic Review of Randomized Controlled Trials

Frequently Asked Questions

What is the Ozempic lawsuit about?

What is a gastric emptying study and do I need one?

What side effects of Ozempic are the lawsuits about?

Will my gastroparesis go away if I stop taking Ozempic?

Can I sue if I used Ozempic for weight loss, not diabetes?

Can the defense argue my diabetes caused my gastroparesis?

Is Mounjaro included in the lawsuit?

I had my gallbladder removed after starting Ozempic. Can I sue?

What is gastroparesis and is it permanent?

I lost weight rapidly on Ozempic and then got gallstones. Is that related?

How much are Ozempic lawsuits worth?

Does the gallbladder warning on the label protect the manufacturer?

What evidence do I need to file an Ozempic lawsuit?

How is pancreatitis diagnosed?

Can I still file an Ozempic lawsuit in 2026?

I had pancreatitis while on Mounjaro. Is my case the same as Ozempic?

What is NAION and how does it relate to Ozempic?

Can pancreatitis from Ozempic lead to long-term problems?

Do I have to stop taking Ozempic to file a lawsuit?

I needed emergency surgery for bowel obstruction while on Wegovy. What are my options?

What is an MDL and how does it affect my case?

Is ileus the same as bowel obstruction?

Will there be a class action settlement for Ozempic?

Did anyone die from Ozempic-related bowel obstruction?

Is NAION vision loss permanent?

Why did Europe add a NAION warning but the U.S. did not?

How do I know if my vision loss is NAION?

Should I wait for bellwether trial results before filing?

How are individual settlements calculated in a pharmaceutical MDL?

What percentage does the lawyer take from an Ozempic settlement?

How big is Novo Nordisk?

Has Novo Nordisk faced lawsuits before?

Can I sue Novo Nordisk if I used generic semaglutide or a compounded version?

Can I file a claim if I used Trulicity instead of Ozempic?

What is the difference between Ozempic and Wegovy?

Is Zepbound safer than Ozempic?

Related Guides

Part of the Ozempic / GLP-1 Investigation